Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Structural basis of ABCF-mediated resistance to pleuromutilin, lincosamide, and streptogramin A antibiotics in Gram-positive pathogens

ABSTRACT: Structural basis of ABCF-mediated resistance to pleuromutilin, lincosamide, and streptogramin A antibiotics in Gram-positive pathogens

PROVIDER: PRJNA680786 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Structural basis for PoxtA-mediated resistance to Phenicol and Oxazolidinone antibiotics

Project description:Structural basis for PoxtA-mediated resistance to Phenicol and Oxazolidinone antibiotics

| PRJNA743321 | ENA

Structural basis for PoxtA-mediated resistance to Phenicol and Oxazolidinone antibiotics

Project description:PoxtA and OptrA are ATP binding cassette (ABC) proteins of the F subtype (ABCF) that confer resistance to oxazolidinone, such as linezolid, and phenicol antibiotics, such as chloramphenicol. PoxtA/OptrA are often encoded on mobile genetic elements, facilitating their rapid spread amongst Gram-positive bacteria. These target protection proteins are thought to confer resistance by binding to the ribosome and dislodging the antibiotics from their binding sites. However, a structural basis for their mechanism of action has been lacking. Here by investigating 5'P mRNA decay intermediates, that provide ribosome protection data, we show that PoxtA protects against Linezolid specific stalls. Furthermore, we present cryo-electron microscopy structures of PoxtA in complex with the Enterococcus faecalis 70S ribosome at 2.9–3.1 Å, as well as the complete E. faecalis 70S ribosome at 2.2–2.5 Å. The structures reveal that PoxtA binds within the ribosomal E-site with its antibiotic resistance domain (ARD) extending towards the peptidyltransferase center (PTC) on the large ribosomal subunit. At its closest point, the ARD of PoxtA is still located >15 Å from the linezolid and chloramphenicol binding sites, suggesting that drug release is elicited indirectly. Instead, we observe that the ARD of PoxtA perturbs the CCA-end of the P-site tRNA causing it to shift by ~4 Å out of the PTC, which correlates with a register shift of one amino acid for the attached nascent polypeptide chain. Given that linezolid and chloramphenicol are context-specific translation elongation inhibitors, we postulate that PoxtA/OptrA confer resistance to oxazolidinones and phenicols indirectly by perturbing the P-site tRNA and thereby altering the conformation of the attached nascent chain to disrupt the drug binding site.

2022-02-12 | GSE179348 | GEO

Structural basis of ABCF-mediated resistance to pleuromutilin, lincosamide, and streptogramin A antibiotics in Gram-positive pathogens

Project description:We present evidence of mechanistically diverse allosteric relays converging on a few peptidyltransferase center (PTC) nucleotides, and propose a general model of antibiotic resistance mediated by these ARE-ABCFs

2021-04-29 | GSE162168 | GEO

An Outer Membrane Protein-Targeting Antibiotic Against Resistant Gram-Negative Bacterial Pathogens

Project description:There is an urgent need for novel antibiotics against carbapenem and 3rd generation cephalosporin-resistant Gram-negative pathogens, for which the last-resort antibiotics have lost most of their efficacy. We describe here a novel class of synthetic antibiotics that was inspired from natural product-derived scaffolds. The antibiotics have an unprecedented mechanism of action, which targets the main component (BamA) of the Bam folding machinery required for folding and insertion of ß-barrel proteins into the outer membrane of Gram-negative bacteria. This OMPTA (outer membrane protein-targeting antibiotic) class shows potent activity against multidrug-resistant Gram-negative ESKAPE pathogens and overcomes colistin-resistance both in vitro and in vivo. A clinical candidate has the potential to address life threatening Gram-negative infections with high unmet medical need.

2020-02-04 | MSV000084899 | MassIVE

Pleuromutilin Antibiotics Suppress Hepatocellular Carcinoma Growth

Project description:Pleuromutilin antibiotics(Lefamulin, Tiamulin, et al) has application potential in malignancies treatment. To mechanistically investigate the inhibitory activity against HCC of Lefamulin and Tiamulin, we treated Hepa1-6 cells with 37 μg/ml Lefamulin or Tiamulin for 2 days. Then the total RNA was performed RNA-Seq analysis.

2026-04-22 | GSE315390 | GEO

An Outer Membrane Protein-Targeting Antibiotic Against Resistant Gram-Negative Bacterial Pathogens

2019-10-22 | PXD010174 | Pride

Pleuromutilin Antibiotics Suppress Hepatocellular Carcinoma Growth

Project description:Pleuromutilin Antibiotics Suppress Hepatocellular Carcinoma Growth

| PRJNA1396644 | ENA

Structural basis for pre-miRNA-31 biogenesis

Project description:Structural basis for pre-miRNA-31 biogenesis

| PRJNA957777 | ENA

Structural Basis for Target-Directed MicroRNA Degradation

Project description:Structural Basis for Target-Directed MicroRNA Degradation

| PRJNA540836 | ENA